Why the study?
Improved childhood cancer survival has led to late metabolic derangements that may contribute to high cardiovascular morbidity and premature mortality.
Childhood cancer survivors face an increased risk of metabolic syndrome and cardiovascular morbidity, highlighting the need for targeted screening and long-term cardiometabolic care.
Answers are grounded in this paper and cite their sources.
Metabolic surveillance may be warranted in childhood cancer survivors; leaves open optimal protocols and prospective validation.
Cancer is a prominent cause of death worldwide in the pediatric population. Since childhood cancer is not possible to prevent, it is essential to focus on a prompt and correct diagnosis followed by effective, evidence-based therapy with individualized supportive care. Given the enhancement of childhood cancer management over the past decades, survival rate has significantly improved, thus leading to the progression of several late effects, including metabolic derangements. These metabolic imbalances are associated with the underlying disease and the cancer treatments. As a result, the metabolic state may contribute to a high risk of cardiovascular morbidity and premature mortality among childhood cancer survivors. This review aims to summarize the potential pathophysiological mechanisms linked to the risk of diabetes and metabolic syndrome and screening recommendations. Further investigations are needed to clarify the underlying mechanisms of such metabolic abnormalities and to improve long-term cardiometabolic survival among these patients.
No takes yet. Share an insight, caveat, or question.
Mainieri et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: